Last reviewed · How we verify
NCT02754752
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
Phase 2 trial testing Electroacupuncture Therapy in Stage I Breast Cancer AJCC v7 in 111 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | supportive care |
| Enrollment | 111 |
| Start date | 13 September 2016 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Electroacupuncture Therapy
- Electroacupuncture Therapy
- Laboratory Biomarker Analysis — full drug profile →
- Quality-of-Life Assessment
- Questionnaire Administration
Conditions studied
- Stage I Breast Cancer AJCC v7 — all drugs for Stage I Breast Cancer AJCC v7 →
- Stage IA Breast Cancer AJCC v7 — all drugs for Stage IA Breast Cancer AJCC v7 →
- Stage IB Breast Cancer AJCC v7 — all drugs for Stage IB Breast Cancer AJCC v7 →
- Stage II Breast Cancer AJCC v6 and v7 — all drugs for Stage II Breast Cancer AJCC v6 and v7 →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, female only, with Stage I Breast Cancer AJCC v7 or Stage IA Breast Cancer AJCC v7. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized phase II trial studies how well electroacupuncture therapy works in reducing chronic pain in patients following surgery for stage I-III breast cancer. Electroacupuncture therapy is a type of complementary integrative medicine in which pulses of weak electrical current are sent through very thin, solid, sterile, stainless steel needles into certain points in the skin. Electroacupuncture therapy may help to lower pain and other surgery-related symptoms.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02754752
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Electroacupuncture Therapy
Trials testing the same drug.
- NCT07074600 — Clinical Efficacy of Electroacupuncture Therapy on Limb Dysfunction in Ischemic Stroke Patients at High-Altitude Regions · NA · not yet recruiting
Other recruiting trials for Stage I Breast Cancer AJCC v7
Currently open trials in the same condition.
- NCT05334069 — Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection · recruiting
- NCT03317405 — Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery · Phase 1 · active not recruiting
- NCT02912312 — Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer · Phase 2 · active not recruiting
- NCT02945579 — Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemi · NA · recruiting
- NCT02954874 — Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer · Phase 3 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02754752 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02754752.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing